Literature DB >> 29715106

3D Culture Represents Apoptosis Induced by Trastuzumab Better than 2D Monolayer Culture.

Takashi Tatara1,2, Toru Mukohara3,4,5, Rina Tanaka6, Yohei Shimono1,7, Yohei Funakoshi1, Yoshinori Imamura1, Masanori Toyoda1, Naomi Kiyota1,4, Midori Hirai6, Yoshihiro Kakeji2, Hironobu Minami1,4.   

Abstract

BACKGROUND: Our hypothesis was that three-dimensional (3D) culture better represents differential in vivo responses to trastuzumab between PIK3CA-wild-type (wt) and mutant (mt) cell lines than does two-dimensional (2D) culture.
MATERIALS AND METHODS: Apoptosis and cell signaling proteins were evaluated in response to trastuzumab with and without BKM120, a pan-phosphatidylinositol 3-kinase (PI3K) inhibitor, using western blot analysis of four breast cancer cell lines with human epidermal growth factor receptor 2 (HER2) amplification.
RESULTS: Increased expression of cleaved poly (ADP-ribose) polymerase (PARP) was observed only in 3D-cultured PIK3CA-wt lines in response to trastuzumab, but not in 2D-cultured PIK3CA-wt or PIK3CA-mt lines. Decrease in the ratio of phosphorylated (p-)AKT to AKT in response to trastuzumab was more profound in PIK3CA-wt cells than in PIK3CA-mt cells in 3D culture, while the difference between PIK3CA genotypes was less apparent in 2D culture. Treatment with BKM120 and trastuzumab resulted in a stronger increase in cleaved PARP than either treatment alone.
CONCLUSION: 3D Culture appears to better represent trastuzumab-induced apoptosis and resistance to trastuzumab associated with PIK3CA mutation. Copyright
© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  3D-culture; Breast cancer; PIK3CA; trastuzumab

Mesh:

Substances:

Year:  2018        PMID: 29715106     DOI: 10.21873/anticanres.12528

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  4 in total

Review 1.  Three-Dimensional 3D Culture Models in Gynecological and Breast Cancer Research.

Authors:  Yarely M Salinas-Vera; Jesús Valdés; Yussel Pérez-Navarro; Gilberto Mandujano-Lazaro; Laurence A Marchat; Rosalio Ramos-Payán; Stephanie I Nuñez-Olvera; Carlos Pérez-Plascencia; César López-Camarillo
Journal:  Front Oncol       Date:  2022-05-26       Impact factor: 5.738

2.  HER2-Targeted Immunotherapy and Combined Protocols Showed Promising Antiproliferative Effects in Feline Mammary Carcinoma Cell-Based Models.

Authors:  Andreia Gameiro; Catarina Nascimento; Jorge Correia; Fernando Ferreira
Journal:  Cancers (Basel)       Date:  2021-04-21       Impact factor: 6.639

3.  Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells.

Authors:  Yumi Fujimoto; Tomoko Yamamori Morita; Akihiro Ohashi; Hiroshi Haeno; Yumi Hakozaki; Masanori Fujii; Yukie Kashima; Susumu S Kobayashi; Toru Mukohara
Journal:  Sci Rep       Date:  2020-12-10       Impact factor: 4.379

4.  UBE2T promotes β-catenin nuclear translocation in hepatocellular carcinoma through MAPK/ERK-dependent activation.

Authors:  Elisavet Lioulia; Panagiotis Mokos; Emmanuel Panteris; Dimitra Dafou
Journal:  Mol Oncol       Date:  2022-03-16       Impact factor: 7.449

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.